Xeris Biopharma Holdings, Inc. (XERS)
| Market Cap | 1.04B |
| Revenue (ttm) | 291.85M |
| Net Income (ttm) | 554,000 |
| Shares Out | 172.43M |
| EPS (ttm) | 0.00 |
| PE Ratio | 1,873.71 |
| Forward PE | 63.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,108,423 |
| Open | 7.08 |
| Previous Close | 6.12 |
| Day's Range | 5.91 - 7.12 |
| 52-Week Range | 3.59 - 10.08 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 10.43 (+73.26%) |
| Earnings Date | Mar 2, 2026 |
About XERS
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adul... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price target is $10.43, which is an increase of 73.26% from the latest price.
News
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Why Are Shares Of Xeris Biopharma Falling Friday?
Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
Recorlev drives robust top-line expansion, while Gvoke and Keveyis provide stable revenue streams in niche, high-need markets, supporting operational leverage. XP-8121, a once-weekly injectable levoth...
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights. "Our ...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. ( XERS) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications Joh...
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy
Xeris Biopharma delivered record Q2 revenue, driven by Recorlev's rapid adoption, and is on track to achieve breakeven in Q3. Recorlev is the primary growth engine, while Gvoke provides steady diversi...
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Comm...
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing
Compared to other biotech companies, Xeris Biopharma Holdings Inc. is a company that has successfully launched products that are already generating revenue. As the company's revenue is expected to gro...
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Announces Details for Analyst & Investor Day
CHICAGO--(BUSINESS WIRE)--Xeris Announces Details for Analyst & Investor Day.
Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pie...
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings
Xeris Biopharma Holdings, Inc. has shown consistent double-digit growth and is expected to continue this trend, with Q1 earnings projected to drive the share price higher. Key metrics to watch include...
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025.